IN CLINICAL TRIALS, BENLYSTA WAS PROVEN TO REDUCE LUPUS SYMPTOMS IN PATIENTS WITH LUPUS

Up to

61%

61%

of patients had reduced disease
activity (SRI-4) at Week 522-4*

* SRI-4 response rate at Week 52 (primary endpoint).

 

IN A CLINICAL TRIAL, BENLYSTA WAS PROVEN TO IMPROVE COMPLETE RENAL RESPONSE IN PATIENTS WITH LUPUS NEPHRITIS

74%

more likely to achieve complete renal response(secondary endpoint)8
(OR=1.74; 95% CI: 1.11, 2.74; P=0.0167)

More patients on BENLYSTA + ST (n=223) vs placebo + ST (n=223) achieved CRR at Week 104; 30% vs 20%, respectively.

 

Primary endpoint: Significantly more BENLYSTA patients (n=223) achieved renal response vs placebo (n=223); 43% vs 32%, respectively (P=0.031).

CI = confidence interval; HR = hazard ratio; OR = odds ratio; SRI = SLE Responder Index; ST = standard therapy.

 

WELL-ESTABLISHED SAFETY PROFILE BASED ON THE LARGEST CLINICAL TRIAL PROGRAM IN LUPUS AND LUPUS NEPHRITIS

7000+

patients with lupus have been
included in trials of BENLYSTA,
including a clinical trial in
patients with lupus nephritis
(N=448)2-4,8-11

WHY BENLYSTA?

Take a minute to listen to Dr. Alvin Wells, Rheumatologist, on why he prescribes BENLYSTA for his appropriate patients.

Paid consultant to GSK at the time of filming.

Organ damage

The impact of BENLYSTA was evaluated in a real-world analysis of organ damage progression.

Icon: Silhouette highlighting organ domains

Does fatigue impact your patients?

Icon: Fatigue

Target underlying disease.
Choose BENLYSTA now.

Image: Woman with yellow circle
Image: Woman with yellow circle